By Justin Petrone

ExonHit Therapeutics this week announced its intentions to spend as much as $32 million in cash and stock to acquire RedPath Integrated Pathology, a clinical molecular lab.

Under the terms of the agreement, the Paris-based drug and diagnostic developer plans to buy RedPath, which sells DNA-based cancer tests, for $12.5 million upfront, another $10 million in stock, and sales milestone payments that could total another $9.5 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.